TransMedics Group (NASDAQ:TMDX) CFO Sells $1,065,211.56 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Gerardo Hernandez sold 7,236 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56. Following the sale, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at $2,162,367.69. The trade was a 33.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Gerardo Hernandez also recently made the following trade(s):

• On Monday, March 2nd, Gerardo Hernandez sold 375 shares of TransMedics Group stock. The stock was sold at an average price of $139.12, for a total transaction of $52,170.00.
• On Thursday, December 4th, Gerardo Hernandez sold 920 shares of TransMedics Group stock. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40.

TransMedics Group Trading Down 0.2%

Shares of NASDAQ:TMDX traded down $0.34 during mid-day trading on Wednesday, reaching $147.66. 701,764 shares of the company were exchanged, compared to its average volume of 830,019. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The firm’s 50-day simple moving average is $134.97 and its 200 day simple moving average is $126.78. TransMedics Group, Inc. has a 1 year low of $62.07 and a 1 year high of $156.00. The firm has a market cap of $5.06 billion, a price-to-earnings ratio of 30.13 and a beta of 1.98.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Whittier Trust Co. of Nevada Inc. increased its stake in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $28,000. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group in the 3rd quarter valued at $29,000. Optiver Holding B.V. raised its stake in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares in the last quarter. Finally, Allworth Financial LP raised its stake in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMDX. Oppenheimer lifted their target price on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday. Needham & Company LLC upped their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.